Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.69 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11408843 | 0.91 | MAPT (0.83) | ALDH1A1GAASMN1; SMN2TDP1MAPT | |
| SCHEMBL10557875 | 0.86 | MAPT (0.75) | ALDH1A1GAASMN1; SMN2MAPTCYP19A1 | |
| SCHEMBL11608031 | 0.86 | MAPT (0.75) | ALDH1A1GAASMN1; SMN2TDP1MAPT | |
| SCHEMBL626949 | 0.84 | MAPT (0.73) | ALDH1A1GAASMN1; SMN2TDP1MAPT | |
| SCHEMBL9416849 | 0.84 | ALDH1A1 (0.56) | ALDH1A1GAASMN1; SMN2TDP1MAPT | |
| SCHEMBL11560418 | 0.84 | CYP19A1 (0.56) | ALDH1A1GAASMN1; SMN2TDP1MAPT | |
| SCHEMBL11560427 | 0.84 | CYP19A1 (0.56) | ALDH1A1GAASMN1; SMN2TDP1MAPT | |
| SCHEMBL11061083 | 0.83 | MAPT (1.00) | ALDH1A1GAASMN1; SMN2TDP1MAPT | |
| SCHEMBL8162593 | 0.83 | MAPT (0.71) | ALDH1A1GAASMN1; SMN2TDP1MAPT | |
| SCHEMBL9977891 | 0.83 | MAPT (0.71) | ALDH1A1GAASMN1; SMN2MAPTCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| WO-2015035051-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-03-12 | — | — | WO | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| CN-1826333-B | Diamine derivatives | DAIICHI SANKYO CO LTD | 2012-12-26 | — | — | CN | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-4160100-A | OXAMIC ACID DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-07-03 | — | — | US | disclosed |
| US-4154961-A | Oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-05-15 | — | — | US | disclosed |
| US-4137325-A | Antisecretory oxamic acid esters | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-01-30 | — | — | US | disclosed |
| US-4099007-A | N,N-SUBSTITUTED 2,4,5-TRIKETOIMIDAZOLIDINES AND A PROCESS FOR THEIR PREPARATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-07-04 | — | — | US | disclosed |
| US-4069343-A | OXAMIC ACID DERIVATIVES FOR THE PREVENTION OF IMMEDIATE TYPE HYPERSENSITIVITY REACTIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-4054666-A | Compositions and methods of treating immediate hypersensitivity reactions with thiazolyl oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054661-A | Pyridyl oxamic acid derivatives and use in the prevention of allergic reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054657-A | Pyrimidinyl oxamic acids and esters, and compositions and methods for the suppression of allergic manifestations | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4036837-A | 2 Alkoxyoxamoyl-pyrazines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-07-19 | — | — | US | disclosed |
| US-3966965-A | Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | NCOA4, SREBF1, ACOX1 | ALDH1A1 88/4885GAA 1050/4885SMN1; SMN2 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.